Experimental HCV Drugs
Experimental HCV Drugs
AASLD 2012: Danoprevir and Mericitabine Work for Prior Non-responders, Hep C Patients with Cirrhosis
- Details
- Category: HCV Treatment
- Published on Monday, 12 November 2012 00:00
- Written by Liz Highleyman
The experimental hepatitis C drugs danoprevir and mericitabine, with or without pegylated interferon and ribavirin, showed good safety and efficacy in previously treated patients, according to findings from the MATTERHORN study presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston. Another analysis from the same trial showed good outcomes for people with liver fibrosis.
Merck Will Soon Start 2 New Trials of MK-5172 in Interferon-free Hepatitis C Regimens
- Details
- Category: HCV Treatment
- Published on Friday, 09 November 2012 00:00
- Written by Press Release
Merck and Co. announced last week that it plans to start 2 new clinical trials to evaluate its investigational hepatitis C virus (HCV) protease inhibitor MK-5172 in all-oral regimens containing ribavirin with or without the company's early-stage NS5A inhibitor MK-8742. Both studies will enroll previously untreated genotype 1 chronic hepatitis C patients.
4-Drug Oral Regimen Cures More than 90% of Chronic Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Tuesday, 23 October 2012 00:00
- Written by Press Release
An all-oral, interferon-free combination regimen containing 3 experimental direct-acting hepatitis C virus (HCV) drugs from Abbott plus ribavirin produced sustained virological response in 99% of previously untreated people with genotype 1 chronic hepatitis C and 93% of patients who experienced prior failure of interferon-based therapy, according to preliminary data from the ongoing Aviator study.
Vertex Announces Agreements to Develop Interferon-free VX-135 Regimens for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Friday, 02 November 2012 00:00
- Written by Press Release
Vertex Pharmaceuticals this week announced that it has made separate agreements with Janssen Pharmaceuticals and GlaxoSmithKline (GSK) to evaluate all-oral regimens containing its HCV polymerase inhibitor VX-135 (also known as ALS-2200) for previously untreated genotype 1 chronic hepatitis C patients.
Interferon-free HCV Treatment: Simeprevir and ALS-2200 Enter Phase 2 All-oral Studies
- Details
- Category: HCV Treatment
- Published on Wednesday, 26 September 2012 00:00
- Written by Press Release
A trio of interferon-free, all-oral regimens for treatment of chronic hepatitis C virus (HCV) are entering Phase 2 clinical trials, the intermediate stage of development after basic safety and antiviral activity have been established, according to recent press releases from Medivir and Vertex. 
More Articles...
- ICAAC 2012: HCV Polymerase Inhibitor Sofosbuvir Appears Safe and Effective for HIV/HCV Coinfected People
- Monoclonal Antibody May Help Prevent and Clear Hepatitis C Virus
- Hepatitis C Candidate BMS-986094 Halted after Death, IDX19368 Gets Clinical Hold
- AIDS 2012: Adding Nitazoxanide Does Not Improve Interferon Cure Rate for HIV/HCV Coinfected Patients
Web Design and Development by